Carlyle invests in Mak-System

The Carlyle Group has made an investment in Mak-System, a provider of software for blood management solutions.

The Carlyle Group has made an investment in Mak-System, a provider of software for blood management solutions. No financial terms were disclosed. In addition to the funding, Philippe Houssiau will become CEO of Mak-System.

PRESS RELEASE

Global investment firm The Carlyle Group (NASDAQ: CG) today announced it has made a significant investment in MAK-SYSTEM (MAK), a family-owned company providing software for blood management solutions, which will be used to accelerate the company’s growth. In conjunction with Carlyle’s investment, the shareholders have decided to name Philippe Houssiau as CEO to help position the business for its next phase of growth.

Founded in 1984 by Simon Kiskovski, MAK is a leading provider of state-of-the-art software solutions supporting the entire blood chain management process, from donation through to transfusion. MAK currently operates on all continents and is considered a preeminent blood management software expert. The company has a strong track record of business success and has built long-term relationships with an established group of blue-chip clients and partners.

The investment will provide MAK with additional capital to support the company’s global growth strategy and to continue innovating and delivering standards of excellence for the blood service, plasma collector and hospital markets.

Simon Kiskovski, Founder of MAK, commented: “We are delighted at the opportunity to be working with Carlyle, one of the most predominant investors in the healthcare space. This partnership will enable us to better serve our clients and rapidly extend our footprint with numerous innovations.”

Jonathan Zafrani, Managing Director at The Carlyle Group, said: “MAK is a very successful, high-quality company, which has established strong capabilities. We are delighted to be working alongside the Kiskovski family and Philippe Houssiau to support the future growth of the company, through product innovation and further international expansion. This investment demonstrates how Carlyle seeks to support companies by leveraging a combination of sector expertise – in this case, healthcare and technology, and our international scale across the world.”

Philippe Houssiau, CEO of MAK, commented: “MAK is a true leader and a pioneer in its field; I look forward working with the MAK team, Carlyle and the Kiskovski family in taking the business to its next phases of development.”

Equity for the transaction comes from Carlyle Europe Partners V (CEP V), a European-focused upper-mid market buyout fund, as well as from Carlyle Europe Technology Partners IV (CETP IV), a pan-European and US fund focusing on growth-oriented investments in telecoms, media and technology. No further financial details were disclosed.About MAK-SYSTEM (MAK)

Established in 1984, MAK is a leading provider of healthcare software solutions for the management of blood, plasma, tissue and cells products.

Further information is available at http://www.mak-system.com.

About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $224 billion of assets under management as of December 31, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 32 offices across six continents. Further information is available at www.carlyle.com. Follow The Carlyle Group on Twitter @OneCarlyle.